(January 20, 2022, 1:47 PM EST) -- WILMINGTON, Del. — A clinical-stage small molecule pharmaceutical company and two of its senior officers violated federal securities laws by misrepresenting the likelihood that the company’s COVID-19 respiratory failure treatment drug would gain approval for use by the U.S. Food and Drug Administration under an emergency use authorization (EUA), a shareholder alleges in a Jan. 18 complaint filed in Delaware federal court....